Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B10f6cf481e14ddb3c8b3ed2cdcb5a71c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B10f6cf481e14ddb3c8b3ed2cdcb5a71c NCIT_P378 "NCI" @default.
- B10f6cf481e14ddb3c8b3ed2cdcb5a71c type Axiom @default.
- B10f6cf481e14ddb3c8b3ed2cdcb5a71c annotatedProperty IAO_0000115 @default.
- B10f6cf481e14ddb3c8b3ed2cdcb5a71c annotatedSource NCIT_C154552 @default.
- B10f6cf481e14ddb3c8b3ed2cdcb5a71c annotatedTarget "A recombinant, humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR-2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous injection, gentuximab specifically binds to VEGFR-2, preventing the binding of its ligand, vascular endothelial growth factor (VEGF). Inhibition of VEGFR-2 signaling may potentially inhibit tumor angiogenesis and decrease nutrient supply to tumor cells, resulting in tumor cell death. VEGFR-2 is a type V receptor tyrosine kinase (RTK) expressed on endothelial cells and some tumor cells that regulates endothelial migration and proliferation." @default.